Alachua and Tampa, Florida, October 1st ( GLOBE NEWSWIRE ) – Axogen, Inc. (" Axogen " or "the Company") (Nasdaq ticker: AXGN) today announced that it has completed the acquisition of BioCircuit Technologies, Inc. (" BioCircuit "). BioCircuit is a private medical device company and also the developer of NerveTape ™.
Axogen, President and CEO, Michael Dale stated: "This is an important day for Axogen as well as for the surgeons and patients we serve. NerveTape represents a new standard of care; it is the first sutureless nerve repair option that is simpler, faster, and more effective than microsurgery. This innovative technology directly meets the daily needs of surgeons in repairing nerves and perfectly aligns with Axogen's mission to restore peripheral nerve function as part of the expected standard of care. Therefore, it is highly suitable for our direct sales team and hospital contracting capabilities, allowing us to unleash and fully utilize the potential of NerveTape."
The company expects that BioCircuit will contribute approximately $6 million in revenue in the fourth quarter of 2026 and about $34 million in revenue in 2027. This contribution has not been included in the latest 2026 annual guidance released by Axogen, which forecasts at least a 24% increase in annual revenue. The company still anticipates that the gross margin for the entire year of 2026 will be at least 73%, and it will achieve positive free cash flow.
About Axogen
Axogen ( AXGN ) is a leading company focused on peripheral nerve regeneration and repair technologies, dedicated to the scientific research, development, and commercialization of related technologies. Axogen employees are passionate about providing patients with peripheral nerve injuries with the opportunity to restore nerve function and quality of life, as well as offering surgeons and healthcare providers innovative, clinically proven, and cost-effective repair solutions. Peripheral nerves provide pathways for motor and sensory signals throughout the body. People suffer from traumatic injuries or undergo surgeries every day, which can affect peripheral nerve function. Physical damage to peripheral nerves, or the inability to reconnect them properly, may lead to loss of muscle or organ function, loss of sensation, or cause pain.
The product portfolio of Axogen includes Avance ® (acellular neural allograft - arwx), Avance ® Nerve Graft, Axoguard Nerve Connector ®, Axoguard Nerve Protector ®, Axoguard HA + Nerve Protector ™, Axoguard Nerve Cap ®, as well as Avive + Soft Tissue Matrix ®.
About BioCircuit Technologies
BioCircuit Technologies is headquartered in Atlanta, Georgia, and develops and commercializes medical devices for peripheral nerve repair and neuromodulation. The company specializes in biomaterials, precision Nitinol design and manufacturing, as well as bioelectronic technologies for neural stimulation and recording. Its first commercial product, NerveTape ™, is the first sutureless device to be approved by FDA for repairing severed nerves. BioCircuit has received funding support from the National Institutes of Health (NIH) and private investments from Alsora Capital, GRA Venture Fund, Masters Capital Management, Michael Masters, and other investors. For more information, please visit www.biocircuit.com.
Warning Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined by Section 27A of the Securities Act of 1933 (as amended) and Section 21E of the Securities Exchange Act of 1934 (as amended). Except for historical facts stated in this press release, all statements are forward-looking statements, including those regarding whether Axogen will be able to successfully integrate BioCircuit and achieve the expected benefits of the acquisition, the expected financial impact of the acquisition, and related financial guidance and prospects (including expected revenue, revenue growth, the revenue contribution of BioCircuit in the fourth quarter of 2026 and 2027, gross margin, free cash flow), as well as the commercialization and adoption of NerveTape, and the expectations for the expansion of Axogen's serviceable market. In some cases, you can identify forward-looking statements through the use of words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “could”, “intend”, “target”, “project”, “contemplates”, “believes”, “estimates”, “predicts”, “potential”, “upcoming”, or “continue”, or their negative forms and other similar expressions. These forward-looking statements are as of the date of this press release and are subject to various risks, uncertainties, and assumptions, including those related to the integration with BioCircuit and achieving the expected benefits of the acquisition, as well as the inherent risks and uncertainties of the Axogen business, including those described in the periodic reports submitted by the company to the U.S. Securities and Exchange Commission (SEC).The events and circumstances reflected in the company's forward-looking statements may not materialize or occur, and actual results may differ significantly from those predicted in the forward-looking statements. For more information regarding the risks faced by Axogen, please refer to the content under the " Risk Factors " heading in the periodic reports submitted by Axogen to SEC, including the Form annual report for the year ending December 31, 2025, and subsequent Form quarterly reports. Do not place excessive reliance on these forward-looking statements, which are only valid as of the date of this document. Except as required by applicable law, Axogen assumes no obligation to update or revise any forward-looking statements contained herein.
Media contact: Axogen, Inc. InvestorRelations @ axogeninc.com
